Economic Assessment of Insulin Glargine and Insulin Determir for Type 2 Diabetes
- VernacularTitle:甘精胰岛素和地特胰岛素治疗2型糖尿病的经济学评估
- Author:
Hengjin DONG
- Publication Type:Journal Article
- Keywords:
Insulin glargine;
Insulin determir;
Glycemia;
Diabetes;
Cost-minimization analysis;
Economic assessment
- From:
China Pharmacy
2001;0(10):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To conduct cost-effective analysis according to clinical trial results of foreign type 2 diabetic patients treated with insulin glargine and insulin determir in order to provide reference for application of basal insulin in China. METHODS: Cost-minimization analysis was used due to the clinical trial results that two kinds of basal insulin had no significant differences in glycemic control. The cost of treatment was detected and evaluated from the perspective of medical insurance. RESULTS: When insulin glargine and insulin determir had same effect on glycemic control and hypoglycemia risk, insulin glargine was 40.77% cheaper than insulin determir in terms of the yearly treatment cost. The cost of treatment of insulin glargine was cheaper than that of insulin glargine although some key factors were adjusted. CONCLUSION: As compared with insulin determir, the cost of treatment is decreased by using insulin glargine for type 2 diabetic patients. Moreover, effect of insulin glargine on glycemic control is the same to insulin determir, which is advantage for controlling the increase of health expenditure.
